| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Chloro-1-tetralone does not have a specific pharmacological target. It is a chemical intermediate used to synthesize other compounds. Its utility lies in its reactivity as a ketone and an aryl halide, allowing for various chemical transformations to build more complex molecular structures. It is a biochemical reagent for biomedical research.
|
|---|---|
| ln Vitro |
6-Chloro-1-tetralone is a crucial step in the production of medicinal substances.
6-Chloro-1-tetralone does not exhibit significant in vitro biological activity relevant to pharmacology. Its primary applications are in organic synthesis. In vitro studies have focused on its chemical properties and its use as a precursor for biologically active molecules. |
| ln Vivo |
6-Chloro-1-tetralone is not a therapeutic agent and does not have in vivo pharmacological activity. It is not administered to animals for therapeutic purposes. Its in vivo effects are primarily toxicological and relate to its use as a chemical intermediate.
|
| Enzyme Assay |
In vitro assays for 6-Chloro-1-tetralone are primarily related to its chemical properties and use as an intermediate. It is not typically used in biological assays. If toxicity is assessed, cytotoxicity assays using mammalian cell lines (e.g., HepG2) would involve exposing cells to various concentrations for 24-48 hours, with cell viability assessed by MTT.
|
| Cell Assay |
Cell-based assays for 6-Chloro-1-tetralone are not typically performed as it is not a pharmaceutical agent. If conducted, they would assess its potential for cytotoxicity rather than therapeutic activity. Human cell lines could be exposed to the compound, and cell viability would be measured.
|
| Animal Protocol |
In vivo animal studies for 6-Chloro-1-tetralone are primarily toxicological and conducted according to regulatory guidelines for industrial chemicals. Acute oral toxicity studies involve administering the compound to rats and monitoring for mortality and clinical signs.
|
| ADME/Pharmacokinetics |
6-Chloro-1-tetralone does not have established pharmacokinetic properties. As a small, lipophilic molecule, it is expected to be absorbed and distributed to tissues, metabolized, and excreted. Its chemical properties are well-documented for industrial applications.
|
| Toxicity/Toxicokinetics |
6-Chloro-1-tetralone is classified as a chemical intermediate with potential toxicity. It may cause skin, eye, and respiratory tract irritation. It is not intended for human or veterinary therapeutic use. Proper handling procedures should be followed.
|
| Additional Infomation |
6-Chloro-1-tetralone is a chlorinated tetralone used as an important intermediate in the synthesis of pharmaceutical compounds. It is not a pharmaceutical agent and does not have therapeutic applications. This compound is for research and industrial use only.
|
| Molecular Formula |
C10H9CLO
|
|---|---|
| Molecular Weight |
180.63
|
| Exact Mass |
180.034
|
| CAS # |
26673-31-4
|
| PubChem CID |
12291149
|
| Appearance |
Colorless to light yellow liquid（Density：1.248 g/cm3）
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
308.6±31.0 °C at 760 mmHg
|
| Flash Point |
146.7±16.0 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC2C(CCCC=2C=1)=O
|
| InChi Key |
WQKHERPPDYPMNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H9ClO/c11-8-4-5-9-7(6-8)2-1-3-10(9)12/h4-6H,1-3H2
|
| Chemical Name |
6-chloro-3,4-dihydro-2H-naphthalen-1-one
|
| Synonyms |
6-Chloro-1-tetralone 5-CHLORO-1-INDOMONE 6-chloro-3 6-Chloro-α-Tetralone 6-Chloro-1-tetralone 5-CHLORO-L-INDOMONE
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5362 mL | 27.6809 mL | 55.3618 mL | |
| 5 mM | 1.1072 mL | 5.5362 mL | 11.0724 mL | |
| 10 mM | 0.5536 mL | 2.7681 mL | 5.5362 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
